Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma
Phase 1
- Conditions
- Refractory Glaucoma
- Interventions
- Registration Number
- NCT00893490
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
This randomized, controlled trial (RCT) compares the efficacy and safety of Ahmed Glaucoma Valve (AGV) implantation alone, with 3 minutes MMC application or with a single layer coverage of amniotic membrane. Outcomes include intraocular eye pressure (IOP), postoperative glaucoma medication and complications. AGV implantation site will be superior or inferior based on indication and these groups will be randomized separately.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- patients with refractory glaucoma
Exclusion Criteria
- children under 7 years old
- adults above 75 years old
- uncooperative patients
- patients underwent the operation for second time
- patients with major operation with AGV
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Ahmed Glaucoma Valve (AGV) alone Ahmed Glaucoma Valve (AGV) - AGV plus MMC Ahmed Glaucoma Valve (AGV) - AGV plus MMC Mitomycin C (MMC) - AGV plus amniotic membrane coverage Ahmed Glaucoma Valve (AGV) - AGV plus amniotic membrane coverage amniotic membrane coverage -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ophthalmic Research Center
🇮🇷Tehran, Iran, Islamic Republic of